Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

7.51
+0.28003.87%
Pre-market: 7.680.1700+2.26%09:10 EDT
Volume:3.90M
Turnover:28.78M
Market Cap:1.64B
PE:-5.31
High:7.57
Open:7.20
Low:7.06
Close:7.23
52wk High:16.44
52wk Low:6.23
Shares:218.91M
Float Shares:185.00M
Volume Ratio:0.94
T/O Rate:2.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4140
EPS(LYR):-1.4203
ROE:-72.99%
ROA:-34.95%
PB:3.16
PE(LYR):-5.29

Loading ...

Canada's Kits Eyecare Q2 Revenue Slightly Beats on Glasses Segment Growth

Reuters
·
Aug 05

EyePoint Pharmaceuticals Q2 Revenue Drops on Lower License Income

Reuters
·
Aug 05

Ocular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says

MT Newswires Live
·
Aug 04

Palvella Therapeutics Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 04

Ocular Therapeutix Faces Governance and Perception Risks from Insider Equity Compensation and Trading Practices

TIPRANKS
·
Aug 04

Stoke Therapeutics Q2 Revenue Falls 33% on Lower Collaboration, Licensing Income

Reuters
·
Aug 04

Analysts Are Bullish on Top Healthcare Stocks: Ocular Therapeutix (OCUL), Twist Bioscience (TWST)

TIPRANKS
·
Aug 04

Ocular Therapeutix Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 03

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Reuters
·
Aug 03

Design Therapeutics Q2 Net Loss Narrower than Expected

Reuters
·
Aug 03

Ocular Therapeutix Q2 Product Revenue Flat, Net Loss Widens on Higher Spending

Reuters
·
Aug 03

Ocular Therapeutix Q2 Product Revenue USD 13.48 Million

THOMSON REUTERS
·
Aug 03

Earnings Flash (OCUL) Ocular Therapeutix Posts Q2 Net Loss $0.35 a Share, vs. FactSet Est of $0.40 Loss

MT Newswires Live
·
Aug 03

Ocular Therapeutix Q2 EPS $(0.35) Beats $(0.40) Estimate, Sales $13.475M Beat $13.199M Estimate

Benzinga Earnings
·
Aug 03

Ocular Therapeutix Q2 FY26 Net Loss Widens to $78.76 Million; Revenue Rises 0.12% to $13.48 Million

Reuters
·
Aug 03

Ocular Therapeutix Grants New Hires Options for 34,700 Shares at $9.66 Each

Reuters
·
Jul 10

Ocular Therapeutix™ Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 10

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 10

OCUL’s OTX-TKI Extension Study: Long-Term Safety Data Could Shape Wet AMD Market

TIPRANKS
·
Jul 02

Does Broad Russell Value Index Inclusion Reshape the Bull Case for Ocular Therapeutix (OCUL)?

Simply Wall St.
·
Jul 01